Fusion Antibodies Plc (GB:FAB) has released an update.
Fusion Antibodies plc, a Belfast-based CRO specializing in antibody engineering for therapeutic and diagnostic applications, has announced their participation in an upcoming investor presentation at Shard Capital Partners LLP’s event on 24 September 2024. The company, known for its proprietary CDRx platform and a track record of over 250 antibodies sequenced since 2012, aims to expedite drug development processes for its clients. Fusion’s growth strategy aligns with the expanding global monoclonal antibody therapeutics market, projected to exceed $445 billion by 2028.
For further insights into GB:FAB stock, check out TipRanks’ Stock Analysis page.
